Phase 1 N=24 Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 0.54; 0.55 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 0.61; 0.54 ng/mL
Phase 1 N=12 Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
Type 2 Diabetes Mellitus
Primary: Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin) — 8.38; 8.78 μmol*hr/L
Phase 1 N=14 Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects
Healthy
Primary: Maximum Concentration (Cmax) of Venlafaxine After Single Dose of Venlafaxine Extended-release (VEN ER) by Metabolizer Status — 26.16; 77.46 ng/mL (90% CI) — p=<0.001
Phase 1 N=24 Olmesartan Pediatric Pharmacokinetic (PK) Study
Hypertension
Primary: For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t) — 7874; 5851 ng/mL*hr
Phase 1 N=136 The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)
Chronic Asthma
Primary: Change From Baseline in FEV1 Over 4 Hours — 0.03; 0.07; 0.13; 0.10 L (Liter)
Phase 1 N=100 Bunionectomy Study (0000-063)
Acute Pain
Primary: Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery — 2.94; 2.07; 5.96 milligrams — p=0.005
Phase 1 N=27 A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)
The Methodology Assessment of Glucose Dependent Insulin Secretion
Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001
Phase 1 N=38 Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 281.111; 257.194 ng/mL
Phase 1 N=50 Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 782.438; 738.531 ng/mL
Phase 1 N=50 Lansoprazole 30 mg DR Capsule Replicate Food Study
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 272.038; 238.043 ng/mL
Phase 1 N=56 Lansoprazole 30 mg DR Capsule Fasting Study
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 939.025; 865.678 ng/mL
Phase 1 N=24 Drug-Food Interaction Study of Seville Orange Juice and Colchicine
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Colchicine — 2,328.44; 1,668.33 pg/mL
Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Atorvastatin
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Colchicine — 2,023.29; 2,487.96 pg/mL
Phase 1 N=72 Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults
End Stage Renal Disease
Primary: Urinary Phosphate Excretion 3-Day Average — 16.01; 17.35 mmol